Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
96.05%
0%
96.05%
6 Months
56.61%
0%
56.61%
1 Year
79.97%
0%
79.97%
2 Years
288.12%
0%
288.12%
3 Years
409.13%
0%
409.13%
4 Years
170.51%
0%
170.51%
5 Years
209.24%
0%
209.24%
MedinCell SA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
54.91%
EBIT Growth (5y)
7.11%
EBIT to Interest (avg)
-7.06
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
4.39
Sales to Capital Employed (avg)
0.64
Tax Ratio
10.43%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-56.65
EV to EBIT
-69.11
EV to EBITDA
-81.38
EV to Capital Employed
-28.90
EV to Sales
35.88
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
No Trend
Bullish
OBV
No Trend
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Mar'23
Mar'23
Mar'22
Change(%)
Net Sales
9.90
4.10
141.46%
Operating Profit (PBDIT) excl Other Income
-26.20
-26.60
1.50%
Interest
3.90
1.80
116.67%
Exceptional Items
-5.20
-0.00
Consolidate Net Profit
-32.00
-24.80
-29.03%
Operating Profit Margin (Excl OI)
-2,814.90%
-6,881.70%
406.68%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2023 is 141.46% vs -50.00% in Mar 2022
Consolidated Net Profit
YoY Growth in year ended Mar 2023 is -29.03% vs -30.53% in Mar 2022
About MedinCell SA 
MedinCell SA
Pharmaceuticals & Biotechnology
Medincell SA is a France-based manufacturer of biological products and pharmaceutical preparations. The Company is focused on the development of therapeutic solutions with worldwide access. The Company works on both for-profit and non-profit projects, in collaboration with partners ranging from pharmaceutical corporations to physicians, from biotechnology firms to academics and foundations. Its range of products consists of three products in development phase: mdc-IRM, a subcutaneous injection in phase III clinical study for the treatment of schizophrenia; mdc-CWM, an intra-articular injection in phase II clinical study for the treatment of post-surgical pain and inflammation; mdc-TJK, a subcutaneous injection for the treatment of schizophrenia, as well as a number of other products that are in the research phase, such as mdc-WWM, which is a subcutaneous injection for contraception, and mdc-ELK, a subcutaneous injection for the treatment of depression, among others.
Company Coordinates 
Company Details
3 rue des Freres Lumiere , JACOU None : 34830
Registrar Details






